|
FDA Announces Funding Opportunity for Digital Health Technologies
The U.S. Food and Drug Administration announced a funding opportunity, open July 20, 2026 – August 20, 2026, for selected applicants to explore the role of digital health technologies (DHTs) (e.g., actigraphy, photography, contactless sensors) in drug development.
Projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on:
- Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs
- Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of contactless room sensors to capture apnea in pediatric patients)
- Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina)
- Capturing early manifestations of chronic diseases (e.g., non-memory related signs of dementia) through the use of DHTs (e.g., tests of balance or slowed reaction time)
For more information, please see RFA-FD-26-012.
|
